Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammatio

Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

Exdensur is the first and only ultra-long-acting biologic in the EU to treat respiratory diseases